Loading…

Loading grant details…

Active HORIZON European Commission

Psych-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness

€10.28M EUR

Funder European Commission
Recipient Organization Universitaet Muenster
Country Germany
Start Date Oct 01, 2022
End Date Sep 30, 2027
Duration 1,825 days
Number of Grantees 29
Roles Coordinator; Participant; Third Party; Associated Partner
Data Source European Commission
Grant ID 101057454
Grant Description

A key problem in Mental Health is that up to one third of patients suffering from major mental disorders develop resistance against drug therapy.

However, patients showing early signs of treatment resistance (TR) do not receive adequate early intensive pharmacological treatment but instead they undergo a stepwise trial-and-error treatment approach.

This situation originates from three major knowledge and translation gaps: i.) we lack effective methods to identify individuals at risk for TR early in the disease process, ii.) we lack effective, personalized treatment strategies grounded in insights into the biological basis of TR, and iii.) we lack efficient processes to translate scientific insights about TR into clinical practice, primary care and treatment guidelines.

It is the central goal of PSYCH-STRATA to bridge these gaps and pave the way for a shift towards a treatment decision-making process tailored for the individual at risk for TR.

To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for TR across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression.

PSYCH-STRATA will i.) dissect the biological basis of TR and establish criteria to enable early detection of individuals at risk for TR based on the integrated analysis of an unprecedented collection of genetic, biological, digital mental health, and clinical data. ii.) Moreover, we will determine effective treatment strategies of individuals at risk for TR early in the treatment process, based on pan-European clinical trials in SCZ, BD and MDD.

These efforts will enable the establishment of novel multimodal machine learning models to predict TR risk and treatment response.

Lastly, iii.) we will enable the translation of these findings into clinical practice by prototyping the integration of personalized treatment decision support and patient-oriented decision-making mental health boards.

All Grantees

Universitaet Muenster; Region Hovedstaden; Ludwig-Maximilians-Universitaet Muenchen; Global Alliance of Mental Illness Advocacy Networks Europe Aisbl; Novamechanics Monoprosopi Ike; Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev; European Research Services Gmbh; Klinikum Der Ludwig-Maximilians-Universitat Munchen; Oslo Universitetssykehus Hf; Universita Degli Studi Di Cagliari; Institut Du Cerveau Et de la Moelle Epiniere; World Psychiatric Association; Fundacion Para la Investigacion Biomedica Del Hospital Gregorio Maranon; Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer; Universitair Medisch Centrum Utrecht; Karlsruher Institut Fuer Technologie; Charite - Universitaetsmedizin Berlin; Universitetet I Oslo; Alma Mater Studiorum - Universita Di Bologna; The University of Adelaide; Hospital Clinic de Barcelona; Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev; Katholieke Universiteit Leuven; Fundacio Centre de Regulacio Genomica; Goeteborgs Universitet; Universita Degli Studi Di Brescia; King's College London; Cardiff University; Kairos Gmbh

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant